Biomarker Menu
Biomarker Menu

Explore Our Biomarker Menu

Including 400+ Biomarker Offerings for a Range of Disease States

Return to Biomarker Menu

Biomarker: sEGFR

Search for Biomarkers





Human Serum


Experienced Running

Required Sample Volume:

50 µL/well


LLOQ: 610 pg/mL
ULOQ: 2,500,000 pg/mL

Biological or Clinical Significance:

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The EGFR is essential for ductal development of the mammary glands, and agonists of the EGFR such as amphiregulin, TGF-α, and heregulin induce both ductal and lobuloalveolar development even in the absence of estrogen and progesterone.

Epidermal Growth Factor Receptor (EGFR) is a gene involved in making cells grow and multiply. EGFR activating mutations are believed to cause the cells to multiply excessively.
Epidermal growth factor (EGF) pathway inhibition is now established as an option for the first-, second- and third-line treatments of non–small-cell lung cancer (NSCLC). Soluble epidermal growth factor receptor (sEGFR/sErbB1) is a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.


Speak to a Scientist

    What would you like to discuss?

    With whom will we be speaking?

    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

    Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.

    biomarker services


    See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

    Explore our services

    case studies

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

    Read our case studies